Research Use Only. Scientific reference for laboratory professionals. Not for human consumption or clinical use. RUO policy

Compound research overview

CJC-1295

CJC-1295 (no DAC) - literature-framed laboratory reference

Introduction

CJC-1295 is a modified GHRH analog studied for effects on GH and IGF-I axes. The VialVibes catalog lists a no-DAC research form. DAC and no-DAC forms differ in half-life engineering; do not assume interchangeability without analytical confirmation.

Chemical and structural summary

Modified GHRH (1-29) analog research material, no DAC. CAS 863288-34-0 commonly referenced. Confirm form and mass on CoA.

Catalog nameCJC-1295 (no DAC)
CategoryGH Axis Research
CAS863288-34-0
Molecular weight noteApproximately 3367 g/mol for no-DAC form (confirm lot CoA)
DocumentationLot-specific CoA available on request

View product specifications and ordering

Research history and background

Published clinical pharmacology studies examined long-acting CJC-1295 constructs (including DAC-related designs) for prolonged GH and IGF-I stimulation with preserved pulsatility in some reports. Mouse GHRH-knockout work has also been used to study growth endpoints.

Areas investigated in laboratory and preclinical research

The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.

  • GHRH receptor pathway research
  • GH / IGF-I axis experimental pharmacology
  • Comparison of long-acting GHRH analogs in published studies

Mechanisms discussed in the literature

As a GHRH analog, CJC-1295 is discussed for increasing GH secretion amplitude/duration depending on formulation. Literature on DAC-containing forms emphasizes albumin binding and extended action; no-DAC material should be interpreted on its own analytical identity.

Key published studies and reviews

Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.

  1. Teichman SL, et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683.
  2. Ionescu M, Frohman LA. (2006). Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. PubMed 17018654.

Known limitations and evidence gaps

Catalog no-DAC research material is not automatically equivalent to every CJC-1295 construct in published trials. Human pharmacology papers describe regulated study settings, not open use of RUO peptides.

Laboratory handling notes

General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.

Regulatory status note

Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.

Scientific reference only - Research Use Only. Content prepared for laboratory professionals. Citations describe published research and do not constitute product claims, medical advice, or authorization for human use of research materials. VialVibes is operated by APEX Research, LLC.

Related research pages